A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
Status:
Completed
Trial end date:
2019-01-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of single and repeated
intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular
degeneration.